Agreement between an in‐house replication competent and a reference replication defective recombinant virus assay for measuring phenotypic resistance to <scp>HIV</scp>‐1 protease, reverse transcriptase, and integrase inhibitorsFrancesco Saladini, Maurizio Zazzi|Journal of Clinical Laboratory Analysis|2017Cited by 26
Polypharmacy, anticholinergic burden and drug–drug interaction assessment in people with four-class-resistant HIV: data from the PRESTIGIO registryMaria Mazzitelli, Laura Comi, Filippo Lagi et al.|Journal of Antimicrobial Chemotherapy|2024Cited by 7
Use of next-generation sequencing on HIV-1 DNA to assess archived resistance in highly treatment-experienced people with multidrug-resistant HIV under virological control: data from the PRESTIGIO RegistryDaniele Armenia, Alessio Bellucci, Vincenzo Spagnuolo et al.|Journal of Antimicrobial Chemotherapy|2024Cited by 6
Residual phenotypic susceptibility to doravirine in multidrug-resistant HIV-1 from subjects enrolled in the PRESTIGIO RegistryFrancesco Saladini, Antonella Castagna|International Journal of Antimicrobial Agents|2023Cited by 6
A Comparison of Sanger Sequencing and Amplicon-Based Next Generation Sequencing Approaches for the Detection of HIV-1 Drug Resistance MutationsCamilla Biba, Francesco Saladini|Viruses|2024Cited by 4